Gastric emptying, stomach acid, bile flow, and colon motility all slow down on these drugs. No one is talking about what that does to a terrain that was already congested.
Protein and minerals are not going "unbroken-down." The stomach's pH is overly-acidic and GLP1 medications do not make the pH less acidic. You're not losing your body's ability to process or absorb. You're losing weight because you're *consuming less.*
It's also interesting to look further into your concerns about biliary disease. 37% more common than placebo. What does that mean in real-world numbers? About 1.5% of people on GLP1 medications experienced gallbladder/biliary disease while 1.2% of people in the control group experienced these problems. For every 370 people on GLP1 over the course of a year, you'd expect 1 extra case of gallbladder/biliary disease.
Even more interesting is the risk for gallbladder/biliary disease was higher in people using GLP1 for weight loss than it was for people using it for diabetes. We know obesity and rapid weight loss are both risk factors for gallstones, so it's likely not as much an effect of the medication as it is an effect of the underlying obesity and the medication resulting in actual weight loss.
you're right that GLP-1s don't directly alter stomach pH. the mechanism is more accurately slowed gastric emptying + reduced gastric acid output secondary to vagal and hormonal changes, not a pH shift itself. fair correction on my framing!
where I'd push back right now is that the absorption picture is more than just reduced caloric intake. protein digestion is impaired on GLP-1s independent of consumption...reduced gastric acid output + delayed gastric emptying + reduced pepsin activation. that's why muscle loss on GLP-1s consistently outpaces what caloric restriction alone predicts. B12, iron, and magnesium absorption issues are documented in 2023-2025 literature independent of weight loss.
on the biliary confounding, it's fair to say that rapid weight loss is an independent gallstone risk factor. but GLP-1s also directly suppress cholecystokinin-mediated gallbladder contraction at the receptor level, independent of weight change.
There is zero evidence of decreased protein absorption or pepsin activation in humans on GLP1 medications, it simply has not been studied. The claim you're pushing back with is not evidence-based. Further, we already understand the muscle loss picture:
People lose more *total muscle* on GLP1 medications than from diet alone because they lose more *total mass* than diet alone. It is proportionally the same. Whether you lose weight with diet, medication, or bariatric surgery, about 25% of the weight loss is lean mass like muscle. There is no concern for affected protein digestion or absorption, there is simply decreased protein intake
On the biliary confounding, obesity is also a clear confounder. If your proposed mechanism of suppressed cholecystokinin-mediated gallbladder contraction was the main factor (it does play a role), then we wouldn't see such a huge difference in biliary disease between people who take GLP1 for diabetes vs people who take it for weight loss.
Protein and minerals are not going "unbroken-down." The stomach's pH is overly-acidic and GLP1 medications do not make the pH less acidic. You're not losing your body's ability to process or absorb. You're losing weight because you're *consuming less.*
It's also interesting to look further into your concerns about biliary disease. 37% more common than placebo. What does that mean in real-world numbers? About 1.5% of people on GLP1 medications experienced gallbladder/biliary disease while 1.2% of people in the control group experienced these problems. For every 370 people on GLP1 over the course of a year, you'd expect 1 extra case of gallbladder/biliary disease.
Even more interesting is the risk for gallbladder/biliary disease was higher in people using GLP1 for weight loss than it was for people using it for diabetes. We know obesity and rapid weight loss are both risk factors for gallstones, so it's likely not as much an effect of the medication as it is an effect of the underlying obesity and the medication resulting in actual weight loss.
you're right that GLP-1s don't directly alter stomach pH. the mechanism is more accurately slowed gastric emptying + reduced gastric acid output secondary to vagal and hormonal changes, not a pH shift itself. fair correction on my framing!
where I'd push back right now is that the absorption picture is more than just reduced caloric intake. protein digestion is impaired on GLP-1s independent of consumption...reduced gastric acid output + delayed gastric emptying + reduced pepsin activation. that's why muscle loss on GLP-1s consistently outpaces what caloric restriction alone predicts. B12, iron, and magnesium absorption issues are documented in 2023-2025 literature independent of weight loss.
on the biliary confounding, it's fair to say that rapid weight loss is an independent gallstone risk factor. but GLP-1s also directly suppress cholecystokinin-mediated gallbladder contraction at the receptor level, independent of weight change.
There is zero evidence of decreased protein absorption or pepsin activation in humans on GLP1 medications, it simply has not been studied. The claim you're pushing back with is not evidence-based. Further, we already understand the muscle loss picture:
People lose more *total muscle* on GLP1 medications than from diet alone because they lose more *total mass* than diet alone. It is proportionally the same. Whether you lose weight with diet, medication, or bariatric surgery, about 25% of the weight loss is lean mass like muscle. There is no concern for affected protein digestion or absorption, there is simply decreased protein intake
On the biliary confounding, obesity is also a clear confounder. If your proposed mechanism of suppressed cholecystokinin-mediated gallbladder contraction was the main factor (it does play a role), then we wouldn't see such a huge difference in biliary disease between people who take GLP1 for diabetes vs people who take it for weight loss.